GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ensol Biosciences Inc (XKRX:140610) » Definitions » Quick Ratio

Ensol Biosciences (XKRX:140610) Quick Ratio : 0.38 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ensol Biosciences Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Ensol Biosciences's quick ratio for the quarter that ended in Dec. 2023 was 0.38.

Ensol Biosciences has a quick ratio of 0.38. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Ensol Biosciences's Quick Ratio or its related term are showing as below:

XKRX:140610' s Quick Ratio Range Over the Past 10 Years
Min: 0.12   Med: 1.92   Max: 12.84
Current: 0.38

During the past 10 years, Ensol Biosciences's highest Quick Ratio was 12.84. The lowest was 0.12. And the median was 1.92.

XKRX:140610's Quick Ratio is ranked worse than
90.71% of 1540 companies
in the Biotechnology industry
Industry Median: 3.58 vs XKRX:140610: 0.38

Ensol Biosciences Quick Ratio Historical Data

The historical data trend for Ensol Biosciences's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ensol Biosciences Quick Ratio Chart

Ensol Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.90 0.53 0.67 0.46 0.38

Ensol Biosciences Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.90 0.53 0.67 0.46 0.38

Competitive Comparison of Ensol Biosciences's Quick Ratio

For the Biotechnology subindustry, Ensol Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ensol Biosciences's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ensol Biosciences's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Ensol Biosciences's Quick Ratio falls into.



Ensol Biosciences Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Ensol Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(4745.769-0)/12575.31
=0.38

Ensol Biosciences's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(4745.769-0)/12575.31
=0.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ensol Biosciences  (XKRX:140610) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Ensol Biosciences Quick Ratio Related Terms

Thank you for viewing the detailed overview of Ensol Biosciences's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Ensol Biosciences (XKRX:140610) Business Description

Traded in Other Exchanges
N/A
Address
51, Techno 10-ro, Yuseong-gu, Daejeon, KOR, 34036
Ensol Biosciences Inc is a Korean big data-driven biopharmaceutical company. The company is engaged in developing drugs for the diseases that have no therapeutic alternatives, such as a degenerative disc, osteoarthritis, cancer, Alzheimer's dementia, and type 1 diabetes. Its drugs portfolio includes Peniel 2000 Drug for Degenerative Disc Disease, Engedi 1000 Drug for Osteoarthritis, Charis 1000 Drug for Immuno-Oncology, Moriah 1000 Drug for Alzheimer's Disease, Shiloah 1000 Drug for Type I Diabetes, and EAD100 Drug for Animal Osteoarthritis.

Ensol Biosciences (XKRX:140610) Headlines

No Headlines